TY - JOUR
T1 - Treatment of onychomycosis: An update
AU - Shirwaikar, A.
AU - Thomas, T.
AU - Shirwaikar, A.
AU - Lobo, R.
AU - Prabhu, K.S.
N1 - Cited By :5
Export Date: 10 November 2017
CODEN: IJSID
Correspondence Address: Shirwaikar, A. A.; Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal 576104, India; email: [email protected]
Chemicals/CAS: amorolfine, 78613-38-4; ciclopirox, 29342-05-0; ciclopiroxolamine, 41621-49-2; erythromycin, 114-07-8, 70536-18-4; fluconazole, 86386-73-4; griseofulvin, 126-07-8; itraconazole, 84625-61-6; ketoconazole, 65277-42-1; terbinafine, 91161-71-6
Tradenames: diflucan; fulvicin; gifulvin; gris peg; lamisil; penlac; sporanox
References: Cohen, P.R., Scher, R.K., Aging (1999) Atlas of hair and nails, pp. 213-225. , Hordinsky MK, Sawaya ME, Scher RK, editors, Philadelphia: Churchill Livingstone;; Roberts, D.T., Taylor, W.D., Boyle, J., Guidelines for treatment of onychomycosis (2003) Br J Dermatol, 148, pp. 402-410; Nathan, A., Treatment of fungal nail infection (2006) Pharm J, 276, pp. 597-600; Iorizzo, M., Piraccini, B.M., Rech, G., Tosti, A., Treatment of onychomycosis with oral antifungal agents (2005) Expert Opin Drug Deliv, 2, pp. 435-440; Gupta, A.K., Schouten, J.R., Lynch, L.E., Ciclopirox nail lacquer 8% for the treatment of onychomycosis: A Canadian perspective (2005) Skin Ther Lett, 10, pp. 1-3; Practice guidance: OTC Amorolfine nail lacquer. London: Royal Pharmaceutical Society of Britain; 2006; Drug Evaluation Monographs, Micromedex, Inc. 76 Exp. (May 31, 1993); Tosti, A., Piraccini, B.M., Lorenzi, S., Iorizzo, M., Treatment of non dermatophyte mold and candida onchomycosis (2003) Dermatol Clin, 21, pp. 491-497; http://www.fda.gov, Available from; http://www.guideline.gov, Available fromUR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-64349104450&doi=10.4103%2f0250-474X.49088&partnerID=40&md5=78f034b13dc229b20eb93ae4eeac7d9c
PY - 2008
Y1 - 2008
N2 - Fungal infections of skin are one of the most common infections in human beings. The areas which are likely to get infected include the scalp, the hands and the feet. Dermatophytes, yeasts and moulds are the three major fungi responsible for skin infections. Earlier oral antifungal agents were used for treatment of fungal infection in finger and toe nails. The disadvantages of oral antifungal agents are toxicity and longer treatment period. Now medicated nail lacquers have been developed for the treatment of fungal infections i.e. onychomycosis, which has less toxicity and shorter treatment period.
AB - Fungal infections of skin are one of the most common infections in human beings. The areas which are likely to get infected include the scalp, the hands and the feet. Dermatophytes, yeasts and moulds are the three major fungi responsible for skin infections. Earlier oral antifungal agents were used for treatment of fungal infection in finger and toe nails. The disadvantages of oral antifungal agents are toxicity and longer treatment period. Now medicated nail lacquers have been developed for the treatment of fungal infections i.e. onychomycosis, which has less toxicity and shorter treatment period.
U2 - 10.4103/0250-474X.49088
DO - 10.4103/0250-474X.49088
M3 - Article
SN - 0250-474X
VL - 70
SP - 710
EP - 714
JO - Indian Journal of Pharmaceutical Sciences
JF - Indian Journal of Pharmaceutical Sciences
IS - 6
ER -